USANA Health Sciences, Inc. announced on April 14, 2025, the successful completion of a clinical study on its Celavive Resurfacing Serum. The study evaluated the product's efficacy and tolerance, demonstrating statistically significant improvements in skin appearance within just two weeks of use.
The clinical study involved 33 women aged 39 to 65 with mild to moderate skin concerns, across various races and ethnicities. Results showed the Resurfacing Serum was well-tolerated by all subjects, with improvements observed in skin measurements taken at two, four, eight, and twelve weeks.
Dr. Kathryn Armstrong, USANA's chief scientific officer, expressed satisfaction with the study's outcome, emphasizing that clinical studies are crucial for demonstrating product efficacy. The Resurfacing Serum is formulated with a blend of alpha/beta hydroxy acids, niacinamide, peptides, and bakuchiol, designed to smooth skin, reduce dark spots, and improve fine lines and wrinkles.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.